Summary:
A massive real-world epidemiological investigation from the UC San Diego School of Medicine reveals that statin medications are associated with a significantly reduced risk of developing open-angle glaucoma and a lower rate of surgical escalation in those already diagnosed.
Analyzing health records from more than 420,000 propensity-matched individuals across a 20-year cohort in the British Journal of Ophthalmology, researchers discovered that statin users had a 15% lower incidence of glaucoma and up to a 55% to 60% reduction in the need for laser or surgical interventions.
Key Facts:
- Lower Glaucoma Incidence: Statin use was associated with a 15% relative risk reduction in developing open-angle glaucoma compared to matched non-users over five years.
- Significant Reduction in Surgical Escalation: Among patients with established glaucoma, statin therapy was linked to a 36% lower risk of incisional surgery, a 55% reduction in minimally invasive glaucoma surgery (MIGS), and a 60% reduction in selective laser trabeculoplasty (SLT).
- Massive International Cohort: The study evaluated electronic health records from a global registry spanning 165 million patients, examining over 210,000 matched pairs followed between August 2006 and August 2026.
Source: UC San Diego School of Medicine / British Journal of Ophthalmology
Glaucoma is one of the leading global causes of irreversible blindness, marked by the progressive and permanent degeneration of retinal ganglion cells and optic nerve axons. While current clinical management focuses almost exclusively on lowering intraocular pressure (IOP) via topical eye drops, laser procedures, or invasive filtering surgeries, mechanical pressure reduction does not always halt neurodegenerative progression.
Statins, the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors taken by tens of millions of adults to manage cardiovascular disease, are increasingly recognized for their pleiotropic properties. Beyond reducing low-density lipoprotein (LDL) cholesterol, statins exhibit potent anti-inflammatory, antioxidant, endothelial-stabilizing, and neuroprotective activities across the central nervous system.
Whether these systemic actions translate into measurable clinical protection for the human optic nerve has remained an unresolved question in ophthalmic medicine.
Now, an observational study led by researchers at the University of California San Diego School of Medicine provides robust population-scale evidence that statins protect against both the development and the clinical progression of glaucoma.
Published online in the British Journal of Ophthalmology, the study shows that statin users not only develop open-angle glaucoma less frequently, but those already living with the condition are significantly less likely to require advanced interventions, such as laser therapy or operating room surgery.
“Glaucoma is one of the leading causes of irreversible blindness, and statins are among the most common medications used to lower cholesterol and reduce the risk of heart disease,” said senior study author Robert Weinreb, M.D., Distinguished Professor in the Viterbi Family Department of Ophthalmology at UC San Diego School of Medicine and Director of both the Hamilton Glaucoma Center and the Gleiberman Center for Glaucoma Research at the Shiley Eye Institute. “If this association is confirmed in future studies, it could have implications for a very large number of people.”
Mining 20 Years of Global Patient Data
To resolve conflicting conclusions from smaller prior trials, the UC San Diego team, collaborating with researchers from the University of South Florida and the University of Southern California, queried a federated global database covering 165 million individuals.
The investigators structured two targeted clinical cohorts:
- Primary Incidence Cohort: The team compared 210,000 adults with a confirmed record of statin use between August 2006 and August 2026 against a meticulously matched control group of 210,000 individuals with no history of statin exposure. Both groups had documented longitudinal ophthalmological examinations. Over five years, 2.3% of the statin cohort developed open-angle glaucoma compared to 2.6% of the control group, representing a statistically significant 15% reduction in incident disease.
- Disease Progression Cohort: In a secondary analysis, researchers tracked more than 30,000 individuals with pre-existing glaucoma taking statins compared with nearly 250,000 glaucoma patients not taking statins.
Shielding the Optic Nerve from Escalating Interventions
In patients already managing glaucoma, statin use was tied to a marked decrease in the need for escalating treatments across both five- and ten-year follow-up windows.
At the five-year mark, statin therapy was associated with:
- A 60% lower risk of undergoing selective laser trabeculoplasty (SLT), a laser procedure that enhances aqueous outflow.
- A 55% reduced risk of requiring minimally invasive glaucoma surgery (MIGS), keyhole microsurgical implants designed to reduce intraocular pressure.
- A 36% lower risk of undergoing traditional, incisional glaucoma surgeries (such as trabeculectomy or tube-shunt drainage implants).
- A 12% reduced risk of needing additional prescription intraocular pressure-lowering eye drops.
These protective associations persisted out to a decade of follow-up, suggesting sustained therapeutic benefit over time.
“Statins are known to have pleiotropic effects beyond cholesterol lowering, including anti-inflammatory and potential neuroprotective properties,” Dr. Weinreb explained. “This study suggests those effects could be relevant to optic nerve health, and future studies will be able to tell us if this is a causal, clinically actionable relationship.”
Caveats and the Path to Randomized Clinical Trials
Because this investigation was retrospective and observational, the authors emphasize that it cannot demonstrate direct causality. Residual confounding factors, such as socioeconomic status, exercise, diet, or overall medication adherence, could influence the observed outcomes.
Furthermore, the database lacked granular physiological metrics, such as baseline intraocular pressure measurements, visual field mean deviation scores, or specific surgical rationales, precluding researchers from verifying whether surgeries were omitted due to milder disease or patient choice.
Nevertheless, given the high safety profile, affordability, and widespread accessibility of statins, the findings provide a strong clinical rationale for prospective, randomized controlled clinical trials to test whether targeted statin regimens can serve as adjuvant neuroprotective therapies to preserve eyesight in glaucoma patients.
Funding: The research was funded, in part, by Research to Prevent Blindness.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this Visual Neuroscience and Neuropharmacology Research:
- Media Contact: Miles Martin
- Source: UCSD
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: British Journal of Ophthalmology (Oct 1, 2026). “Statin use is associated with lower risk of open-angle glaucoma incidence and treatment escalation.” Authors: Forest Lin, Alexander T. Hong, and Robert N. Weinreb.
- DOI: 10.1136/bjo-2026-330339
Abstract
Statin use is associated with lower risk of open-angle glaucoma incidence and treatment escalation
Background
Retrospective cohort study using the TriNetX database to explore the relationship between statin use and glaucoma.
Methods
The open-angle glaucoma (OAG) incidence analysis consisted of individuals over 40 years of age with statin use and ophthalmological follow-up within 1 year prior. The OAG treatment analysis consisted of individuals with glaucoma and concurrent statin use. Outcomes included rates of OAG onset, topical ocular hypotensive prescription, incisional glaucoma surgery, minimally invasive glaucoma surgery (MIGS) and selective laser trabeculoplasty (SLT).
Results
210 701 matched patients were included in the OAG incidence analysis and 29 598 in the OAG treatment analysis. At 5 years, statin use was associated with lower risk of OAG incidence (HR 0.85 (95% CI 0.82 to 0.89)), as well as treatment escalation to incisional glaucoma surgery (HR 0.64 (95% CI 0.58 to 0.71)), MIGS (HR 0.45 (95% CI 0.41 to 0.50)) or SLT (HR 0.40 (95% CI 0.36 to 0.44)) and lower rates of topical ocular hypotensive prescription (HR 0.89 (95% CI 0.86 to 0.91)). At 10 years, statin use was associated with lower risk of OAG incidence (HR 0.90 (95% CI 0.87 to 0.93)), escalation to incisional glaucoma surgery (HR 0.68 (95% CI 0.63 to 0.75)), MIGS (HR 0.54 (95% CI 0.49 to 0.59)) or SLT (HR 0.49 (95% CI 0.45 to 0.52)) and lower rates of topical ocular hypotensive prescription (HR 0.88 (95% CI 0.86 to 0.91)).
Conclusions
Our results suggest that statin use is associated with lower risk of glaucoma onset and treatment escalation. Prospective trials are needed to further elucidate the relationship between statin usage and glaucoma.
